Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone.

Khalilieh S, Yee KL, Sanchez RI, Vaynshteyn K, Fan L, Searle S, Bouhajib M, Iwamoto M.

Clin Pharmacol Drug Dev. 2019 May 23. doi: 10.1002/cpdd.699. [Epub ahead of print]

PMID:
31120195
2.

Evaluation of the Pharmacokinetics of Metformin Following Coadministration With Doravirine in Healthy Volunteers.

Sanchez RI, Yee KL, Fan L, Cislak D, Martell M, Jordan HR, Iwamoto M, Khalilieh S.

Clin Pharmacol Drug Dev. 2019 Apr 11. doi: 10.1002/cpdd.685. [Epub ahead of print]

PMID:
30973682
3.

A Study to Evaluate Doravirine Pharmacokinetics When Coadministered With Acid-Reducing Agents.

Khalilieh SG, Yee KL, Sanchez RI, Fan L, Vaynshteyn K, Deschamps K, Martell M, Jordan HR, Iwamoto M.

J Clin Pharmacol. 2019 Aug;59(8):1093-1098. doi: 10.1002/jcph.1399. Epub 2019 Feb 28.

PMID:
30817001
4.

Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.

Khalilieh SG, Yee KL, Sanchez RI, Fan L, Anderson MS, Sura M, Laethem T, Rasmussen S, van Bortel L, van Lancker G, Iwamoto M.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02016-18. doi: 10.1128/AAC.02016-18. Print 2019 May.

5.

Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir.

Ankrom W, Sanchez RI, Yee KL, Fan L, Mitra P, Wolford D, Triantafyllou I, Sterling LM, Stoch SA, Iwamoto M, Khalilieh S.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02491-18. doi: 10.1128/AAC.02491-18. Print 2019 May.

6.

In Vitro Evaluation of the Drug Interaction Potential of Doravirine.

Bleasby K, Fillgrove KL, Houle R, Lu B, Palamanda J, Newton DJ, Lin M, Chan GH, Sanchez RI.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02492-18. doi: 10.1128/AAC.02492-18. Print 2019 Apr.

7.

Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention.

Barrett SE, Teller RS, Forster SP, Li L, Mackey MA, Skomski D, Yang Z, Fillgrove KL, Doto GJ, Wood SL, Lebron J, Grobler JA, Sanchez RI, Liu Z, Lu B, Niu T, Sun L, Gindy ME.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01058-18. doi: 10.1128/AAC.01058-18. Print 2018 Oct.

8.

Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics.

Ankrom W, Yee KL, Sanchez RI, Adedoyin A, Fan L, Marbury T, Preston RA, Iwamoto M, Khalilieh SG.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00326-18. doi: 10.1128/AAC.00326-18. Print 2018 Aug.

9.

Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects.

Khalilieh SG, Yee KL, Sanchez RI, Liu R, Fan L, Martell M, Jordan H, Iwamoto M.

J Clin Pharmacol. 2018 May 3. doi: 10.1002/jcph.1103. [Epub ahead of print]

PMID:
29723418
10.

Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans.

Sanchez RI, Fillgrove KL, Yee KL, Liang Y, Lu B, Tatavarti A, Liu R, Anderson MS, Behm MO, Fan L, Li Y, Butterton JR, Iwamoto M, Khalilieh SG.

Xenobiotica. 2019 Apr;49(4):422-432. doi: 10.1080/00498254.2018.1451667. Epub 2018 Mar 28.

PMID:
29557716
11.

The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.

Yee KL, Khalilieh SG, Sanchez RI, Liu R, Anderson MS, Manthos H, Judge T, Brejda J, Butterton JR.

Clin Drug Investig. 2017 Jul;37(7):659-667. doi: 10.1007/s40261-017-0513-4.

PMID:
28353169
12.

Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics.

Khalilieh S, Yee KL, Liu R, Fan L, Sanchez RI, Auger P, Triantafyllou I, Stypinski D, Lasseter KC, Marbury T, Iwamoto M.

J Clin Pharmacol. 2017 Jun;57(6):777-783. doi: 10.1002/jcph.857. Epub 2016 Dec 27.

PMID:
28026013
13.

Identification of proximal biomarkers of PKC agonism and evaluation of their role in HIV reactivation.

Vemula SV, Maxwell JW, Nefedov A, Wan BL, Steve J, Newhard W, Sanchez RI, Tellers D, Barnard RJ, Blair W, Hazuda D, Webber AL, Howell BJ.

Antiviral Res. 2017 Mar;139:161-170. doi: 10.1016/j.antiviral.2016.11.014. Epub 2016 Nov 23.

PMID:
27889530
14.

Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study.

Khalilieh S, Yee KL, Sanchez RI, Triantafyllou I, Fan L, Maklad N, Jordan H, Martell M, Iwamoto M.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01364-16. doi: 10.1128/AAC.01364-16. Print 2017 Feb.

15.

Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.

Yee KL, Sanchez RI, Auger P, Liu R, Fan L, Triantafyllou I, Lai MT, Di Spirito M, Iwamoto M, Khalilieh SG.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01757-16. doi: 10.1128/AAC.01757-16. Print 2017 Feb.

16.

Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding Group.

Bungard CJ, Williams PD, Ballard JE, Bennett DJ, Beaulieu C, Bahnck-Teets C, Carroll SS, Chang RK, Dubost DC, Fay JF, Diamond TL, Greshock TJ, Hao L, Holloway MK, Felock PJ, Gesell JJ, Su HP, Manikowski JJ, McKay DJ, Miller M, Min X, Molinaro C, Moradei OM, Nantermet PG, Nadeau C, Sanchez RI, Satyanarayana T, Shipe WD, Singh SK, Truong VL, Vijayasaradhi S, Wiscount CM, Vacca JP, Crane SN, McCauley JA.

ACS Med Chem Lett. 2016 May 9;7(7):702-7. doi: 10.1021/acsmedchemlett.6b00135. eCollection 2016 Jul 14.

17.

Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors.

Greshock TJ, Sanders JM, Drolet RE, Rajapakse HA, Chang RK, Kim B, Rada VL, Tiscia HE, Su H, Lai MT, Sur SM, Sanchez RI, Bilodeau MT, Renger JJ, Kern JT, McCauley JA.

Bioorg Med Chem Lett. 2016 Jun 1;26(11):2631-5. doi: 10.1016/j.bmcl.2016.04.021. Epub 2016 Apr 9.

PMID:
27106707
18.

A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.

Kovarova M, Swanson MD, Sanchez RI, Baker CE, Steve J, Spagnuolo RA, Howell BJ, Hazuda DJ, Garcia JV.

J Antimicrob Chemother. 2016 Jun;71(6):1586-96. doi: 10.1093/jac/dkw042. Epub 2016 Mar 21.

19.

Discovery of MK-8970: an acetal carbonate prodrug of raltegravir with enhanced colonic absorption.

Walji AM, Sanchez RI, Clas SD, Nofsinger R, de Lera Ruiz M, Li J, Bennet A, John C, Bennett DJ, Sanders JM, Di Marco CN, Kim SH, Balsells J, Ceglia SS, Dang Q, Manser K, Nissley B, Wai JS, Hafey M, Wang J, Chessen G, Templeton A, Higgins J, Smith R, Wu Y, Grobler J, Coleman PJ.

ChemMedChem. 2015 Feb;10(2):245-52. doi: 10.1002/cmdc.201402393. Epub 2014 Dec 2.

PMID:
25469982
20.

Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques.

Del Prete GQ, Shoemaker R, Oswald K, Lara A, Trubey CM, Fast R, Schneider DK, Kiser R, Coalter V, Wiles A, Wiles R, Freemire B, Keele BF, Estes JD, Quiñones OA, Smedley J, Macallister R, Sanchez RI, Wai JS, Tan CM, Alvord WG, Hazuda DJ, Piatak M Jr, Lifson JD.

Antimicrob Agents Chemother. 2014 Nov;58(11):6790-806. doi: 10.1128/AAC.03746-14. Epub 2014 Sep 2.

21.

Design of prodrugs to enhance colonic absorption by increasing lipophilicity and blocking ionization.

Nofsinger R, Clas SD, Sanchez RI, Walji A, Manser K, Nissley B, Balsells J, Nair A, Dang Q, Bennett DJ, Hafey M, Wang J, Higgins J, Templeton A, Coleman P, Grobler J, Smith R, Wu Y.

Pharmaceuticals (Basel). 2014 Feb 24;7(2):207-19. doi: 10.3390/ph7020207.

22.

Chemistry-enabled drug delivery (prodrugs): recent progress and challenges.

Clas SD, Sanchez RI, Nofsinger R.

Drug Discov Today. 2014 Jan;19(1):79-87. doi: 10.1016/j.drudis.2013.08.014. Epub 2013 Aug 27. Review.

PMID:
23993918
23.

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber RD, Piccart-Gebhart MJ, Cameron D.

Lancet Oncol. 2013 Mar;14(3):244-8. doi: 10.1016/S1470-2045(13)70017-2. Epub 2013 Feb 13.

PMID:
23414588
24.

Co-conformational isomerism in a neutral ion-paired supramolecular system.

Cervantes R, Sánchez RI, Tiburcio J.

Chemistry. 2013 Mar 18;19(12):4051-7. doi: 10.1002/chem.201203483. Epub 2013 Jan 22.

PMID:
23341149
25.

Strategies towards improving the pharmacokinetic profile of ε-substituted lysinol-derived HIV protease inhibitors.

Rajapakse HA, Walji AM, Moore KP, Zhu H, Mitra AW, Gregro AR, Tinney E, Burlein C, Touch S, Paton BL, Carroll SS, DiStefano DJ, Lai MT, Grobler JA, Sanchez RI, Williams TM, Vacca JP, Nantermet PG.

ChemMedChem. 2011 Feb 7;6(2):253-7. doi: 10.1002/cmdc.201000395. Epub 2010 Dec 29. No abstract available.

PMID:
21275047
26.

Epsilon substituted lysinol derivatives as HIV-1 protease inhibitors.

Jones KL, Holloway MK, Su HP, Carroll SS, Burlein C, Touch S, DiStefano DJ, Sanchez RI, Williams TM, Vacca JP, Coburn CA.

Bioorg Med Chem Lett. 2010 Jul 15;20(14):4065-8. doi: 10.1016/j.bmcl.2010.05.082. Epub 2010 May 25.

PMID:
20547452
27.

Dietary clofibrate stimulates the formation and size of estradiol-induced breast tumors in female August-Copenhagen Irish (ACI) rats.

Mesia-Vela S, Sanchez RI, Roberts KG, Reuhl KR, Conney AH, Kauffman FC.

Toxicology. 2008 Apr 3;246(1):63-72. doi: 10.1016/j.tox.2007.12.025. Epub 2008 Jan 6.

28.

Phenobarbital treatment inhibits the formation of estradiol-dependent mammary tumors in the August-Copenhagen Irish rat.

Mesia-Vela S, Sanchez RI, Reuhl KR, Conney AH, Kauffman FC.

J Pharmacol Exp Ther. 2006 May;317(2):590-7. Epub 2006 Jan 18.

PMID:
16421288
29.

Inhibition of gastric H+,K+-ATPase activity by flavonoids, coumarins and xanthones isolated from Mexican medicinal plants.

Reyes-Chilpa R, Baggio CH, Alavez-Solano D, Estrada-Muñiz E, Kauffman FC, Sanchez RI, Mesia-Vela S.

J Ethnopharmacol. 2006 Apr 21;105(1-2):167-72. Epub 2005 Nov 28.

PMID:
16314059
30.

The effects of steroidal estrogens in ACI rat mammary carcinogenesis: 17beta-estradiol, 2-hydroxyestradiol, 4-hydroxyestradiol, 16alpha-hydroxyestradiol, and 4-hydroxyestrone.

Turan VK, Sanchez RI, Li JJ, Li SA, Reuhl KR, Thomas PE, Conney AH, Gallo MA, Kauffman FC, Mesia-Vela S.

J Endocrinol. 2004 Oct;183(1):91-9.

PMID:
15525577
31.

Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant.

Sanchez RI, Wang RW, Newton DJ, Bakhtiar R, Lu P, Chiu SH, Evans DC, Huskey SE.

Drug Metab Dispos. 2004 Nov;32(11):1287-92. Epub 2004 Aug 10.

PMID:
15304427
32.

The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol.

Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE.

Drug Metab Dispos. 2004 Nov;32(11):1209-12. Epub 2004 Aug 10.

PMID:
15304426
33.

Dietary clofibrate inhibits induction of hepatic antioxidant enzymes by chronic estradiol in female ACI rats.

Mesia-Vela S, Sanchez RI, Reuhl KR, Conney AH, Kauffman FC.

Toxicology. 2004 Aug 5;200(2-3):103-11.

PMID:
15212807
36.

Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets.

Huskey SE, Dean BJ, Bakhtiar R, Sanchez RI, Tattersall FD, Rycroft W, Hargreaves R, Watt AP, Chicchi GG, Keohane C, Hora DF, Chiu SH.

Drug Metab Dispos. 2003 Jun;31(6):785-91.

PMID:
12756213
37.

Challenges of cancer drug design: a drug metabolism perspective.

Sanchez RI, Mesia-Vela S, Kauffman FC.

Curr Cancer Drug Targets. 2001 May;1(1):1-32. Review.

PMID:
12188889
38.

Catechol estrogen formation in liver microsomes from female ACI and Sprague-Dawley rats: comparison of 2- and 4-hydroxylation revisited.

Mesia-Vela S, Sanchez RI, Li JJ, Li SA, Conney AH, Kauffman FC.

Carcinogenesis. 2002 Aug;23(8):1369-72.

PMID:
12151356
39.

Natural products isolated from Mexican medicinal plants: novel inhibitors of sulfotransferases, SULT1A1 and SULT2A1.

Mesía-Vela S, Sańchez RI, Estrada-Muñiz E, Alavez-Solano D, Torres-Sosa C, Jiménez M, Estrada, Reyes-Chilpa R, Kauffman FC.

Phytomedicine. 2001 Nov;8(6):481-8.

PMID:
11824526
40.

Electrochemiluminescence-based detection of beta-lactam antibiotics and beta-lactamases.

Liang P, Sanchez RI, Martin MT.

Anal Chem. 1996 Jul 15;68(14):2426-31.

PMID:
8686931
41.

Spectrophotometric quantitation of silver in X-ray film images and silver-stained electrophoresis gel bands.

Sanchez RI, Darsley MJ, Martin MT.

Anal Biochem. 1995 Jan 1;224(1):190-4.

PMID:
7710070
43.

Isoabzymes: structurally and mechanistically similar catalytic antibodies from the same immunization.

Angeles TS, Smith RG, Darsley MJ, Sugasawara R, Sanchez RI, Kenten J, Schultz PG, Martin MT.

Biochemistry. 1993 Nov 16;32(45):12128-35.

PMID:
8218291
44.

[Effect of various drugs on intradermal skin tests].

Sánchez RI, Lara S, Canseco C Jr.

Alergia. 1977 Jul;24(3):101-6. Spanish. No abstract available.

PMID:
21595

Supplemental Content

Loading ...
Support Center